A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
Public ClinicalTrials.gov record NCT06121843. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1, Multicenter, Open-label Study to Evaluate the Safety and Preliminary Efficacy of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma and Determine the Recommended Dose for Each Add-on Investigational Component
Study identification
- NCT ID
- NCT06121843
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
- Industry
- Enrollment
- 147 participants
Conditions and interventions
Conditions
Interventions
- Alnuctamab Drug
- BMS-986393 Drug
- Elranatamab Drug
- Iberdomide Drug
- Mezigdomide Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 21, 2024
- Primary completion
- Jul 31, 2028
- Completion
- Jul 31, 2028
- Last update posted
- Feb 17, 2026
2024 – 2028
United States locations
- U.S. sites
- 17
- U.S. states
- 13
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham | Birmingham | Alabama | 35294-3300 | Recruiting |
| Mayo Clinic in Arizona - Phoenix | Phoenix | Arizona | 85054 | Recruiting |
| City of Hope Comprehensive Cancer Center | Duarte | California | 91010 | Recruiting |
| Mayo Clinic in Florida | Jacksonville | Florida | 32224 | Recruiting |
| Northside Hospital | Atlanta | Georgia | 30342 | Recruiting |
| Beth Israel Deaconess Medical Center | Boston | Massachusetts | 02215 | Recruiting |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | Recruiting |
| Mayo Clinic in Rochester, Minnesota | Rochester | Minnesota | 55905 | Recruiting |
| University Of Nebraska Medical Center | Omaha | Nebraska | 68198 | Recruiting |
| John Theurer Cancer Center at Hackensack University Medical Center | Hackensack | New Jersey | 07601 | Recruiting |
| Roswell Park Cancer Institute | Buffalo | New York | 14263 | Recruiting |
| Laura and Isaac Perlmutter Cancer Center | New York | New York | 10016 | Recruiting |
| Local Institution - 0009 | New York | New York | 10032 | Completed |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | Recruiting |
| Local Institution - 0023 | Pittsburgh | Pennsylvania | 15232 | Withdrawn |
| Tennessee Oncology | Nashville | Tennessee | 37203 | Recruiting |
| University of Texas MD Anderson Cancer Center | Houston | Texas | 77030 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06121843, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 17, 2026 · Synced May 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06121843 live on ClinicalTrials.gov.